These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 35750138)

  • 1. Soluble TREM2 levels reflect the recruitment and expansion of TREM2
    Hendrikx T; Porsch F; Kiss MG; Rajcic D; Papac-Miličević N; Hoebinger C; Goederle L; Hladik A; Shaw LE; Horstmann H; Knapp S; Derdak S; Bilban M; Heintz L; Krawczyk M; Paternostro R; Trauner M; Farlik M; Wolf D; Binder CJ
    J Hepatol; 2022 Nov; 77(5):1373-1385. PubMed ID: 35750138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TREM2 Regulates the Removal of Apoptotic Cells and Inflammatory Processes during the Progression of NAFLD.
    Liebold I; Meyer S; Heine M; Kuhl A; Witt J; Eissing L; Fischer AW; Koop AC; Kluwe J; Wiesch JSZ; Wehmeyer M; Knippschild U; Scheja L; Heeren J; Bosurgi L; Worthmann A
    Cells; 2023 Jan; 12(3):. PubMed ID: 36766683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-associated macrophages' promotion of fibrosis resolution during MASH regression requires TREM2.
    Ganguly S; Rosenthal SB; Ishizuka K; Troutman TD; Rohm TV; Khader N; Aleman-Muench G; Sano Y; Archilei S; Soroosh P; Olefsky JM; Feldstein AE; Kisseleva T; Loomba R; Glass CK; Brenner DA; Dhar D
    Proc Natl Acad Sci U S A; 2024 Aug; 121(35):e2405746121. PubMed ID: 39172787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine receptor D2 antagonism normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis.
    Qing J; Ren Y; Zhang Y; Yan M; Zhang H; Wu D; Ma Y; Chen Y; Huang X; Wu Q; Mazhar M; Wang L; Liu J; Ding BS; Cao Z
    J Hepatol; 2022 Feb; 76(2):394-406. PubMed ID: 34648896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
    Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
    Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis.
    Krenkel O; Hundertmark J; Abdallah AT; Kohlhepp M; Puengel T; Roth T; Branco DPP; Mossanen JC; Luedde T; Trautwein C; Costa IG; Tacke F
    Gut; 2020 Mar; 69(3):551-563. PubMed ID: 31076404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting EFHD2 inhibits interferon-γ signaling and ameliorates non-alcoholic steatohepatitis.
    Fu JT; Liu J; Wu WB; Chen YT; Lu GD; Cao Q; Meng HB; Tong J; Zhu JH; Wang XJ; Liu Y; Zhuang C; Sheng C; Shen FM; Liu X; Wang H; Yu Y; Zhang Y; Liang HY; Zhang JB; Li DJ; Li X; Wang ZB; Wang P
    J Hepatol; 2024 Sep; 81(3):389-403. PubMed ID: 38670321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exercise of high intensity ameliorates hepatic inflammation and the progression of NASH.
    Fredrickson G; Barrow F; Dietsche K; Parthiban P; Khan S; Robert S; Demirchian M; Rhoades H; Wang H; Adeyi O; Revelo XS
    Mol Metab; 2021 Nov; 53():101270. PubMed ID: 34118476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulating sphingosine 1-phosphate receptor signaling skews intrahepatic leukocytes and attenuates murine nonalcoholic steatohepatitis.
    Liao CY; Barrow F; Venkatesan N; Nakao Y; Mauer AS; Fredrickson G; Song MJ; Sehrawat TS; Dasgupta D; Graham RP; Revelo XS; Malhi H
    Front Immunol; 2023; 14():1130184. PubMed ID: 37153573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
    Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
    J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution.
    Yu W; Zhang Y; Sun L; Huang W; Li X; Xia N; Chen X; Wikana LP; Xiao Y; Chen M; Han S; Wang Z; Pu L
    Metabolism; 2024 Jun; 155():155911. PubMed ID: 38609037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TREM2 protects against inflammation by regulating the release of mito-DAMPs from hepatocytes during liver fibrosis.
    Shan S; Chao S; Liu Z; Wang S; Liu Z; Zhang C; Cheng D; Su Z; Song F
    Free Radic Biol Med; 2024 Aug; 220():154-165. PubMed ID: 38710340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic TREM2
    Lee KJ; An S; Kim MY; Kim SM; Jeong WI; Ko HJ; Yang YM; Noh M; Han YH
    Immunol Cell Biol; 2023 Mar; 101(3):216-230. PubMed ID: 36529983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic danger signaling triggers TREM2
    Zhou L; Qiu X; Meng Z; Liu T; Chen Z; Zhang P; Kuang H; Pan T; Lu Y; Qi L; Olson DP; Xu XZS; Chen YE; Li S; Lin JD
    Sci Transl Med; 2024 Mar; 16(738):eadk1866. PubMed ID: 38478630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RIP1 kinase activity promotes steatohepatitis through mediating cell death and inflammation in macrophages.
    Tao L; Yi Y; Chen Y; Zhang H; Orning P; Lien E; Jie J; Zhang W; Xu Q; Li Y; Ding Z; Wu C; Ding Q; Wang J; Zhang J; Weng D
    Cell Death Differ; 2021 Apr; 28(4):1418-1433. PubMed ID: 33208891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent Manner.
    Jaitin DA; Adlung L; Thaiss CA; Weiner A; Li B; Descamps H; Lundgren P; Bleriot C; Liu Z; Deczkowska A; Keren-Shaul H; David E; Zmora N; Eldar SM; Lubezky N; Shibolet O; Hill DA; Lazar MA; Colonna M; Ginhoux F; Shapiro H; Elinav E; Amit I
    Cell; 2019 Jul; 178(3):686-698.e14. PubMed ID: 31257031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deficient chaperone-mediated autophagy in macrophage aggravates inflammation of nonalcoholic steatohepatitis by targeting Nup85.
    Zhang M; Tian SY; Ma SY; Zhou X; Zheng XH; Li B; Guo GY; Yu JH; Su R; Yang FF; Hu YN; Ma G; Yang H; Zheng LH; Guo CC; Shang YL; Wang JB; Han Y
    Liver Int; 2023 May; 43(5):1021-1034. PubMed ID: 36912786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
    Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
    JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression.
    Guillot A; Winkler M; Silva Afonso M; Aggarwal A; Lopez D; Berger H; Kohlhepp MS; Liu H; Özdirik B; Eschrich J; Ma J; Peiseler M; Heymann F; Pendem S; Mahadevan S; Gao B; Diehl L; Gupta R; Tacke F
    Hepatology; 2023 Jul; 78(1):150-166. PubMed ID: 36630995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.